問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberML21209

2008-06-01 - 2010-12-31

Phase II

Terminated7

ICD-10C18.8

Malignant neoplasm of overlapping sites of colon

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9153.8

Malignant neoplasm of other specified sites of large intestine

A phase II trial of neoadjuvant therapy of bevacizumab in combination with Oxaliplatin and Capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable liver metastasis

  • Trial Applicant

  • Sponsor

  • Trial scale

    Taiwan Multiple Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator Chung Rong Changchien Division of Colorectal Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Jen-Jyn Lin Division of Colorectal Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator CHOU-CHEN CHEN Division of Colorectal Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 陳鴻華 Division of Colorectal Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 王正儀 Division of Colorectal Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 劉美瑾 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chieh-Han Chuang Division of Gastroenterological Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

The metastatic colorectal cancer

Objectives

To assess the resection rate of the liver metastasis with the neoadjuvant regimen of Bevacizumab in combination with Oxaliplatin and Capectabine (XELOX) in metastatic colorectal cancer with unresectable liver metastasis.

Test Drug

Bevacizumab(Avastin)

Active Ingredient

Bevacizumab

Dosage Form

Dosage

100 mg

Endpoints

A

Inclution Criteria

A

Exclusion Criteria

N/A

The Estimated Number of Participants

  • Taiwan

    45 participants

  • Global

    0 participants